Main Page | Risk Factors | Reducing Your Risk | Screening | Symptoms | Diagnosis | Treatment Overview | Chemotherapy | Radiation Therapy | Surgical Procedures | Other Treatments | Lifestyle Changes | Living With Lung Cancer | Talking to Your Doctor | Resource Guide
The diagnosis and prognosis of lung cancer includes the following:
The doctor will ask about your symptoms and medical history. He or she will ask when you first noticed the symptoms and how they may have progressed. The doctor will also ask about anything that may increase your risk of lung cancer, including:
The doctor will perform a physical exam, listen to your lungs, and assess your general health. Your overall health may affect your treatment plan. Abnormalities in other parts of the body may indicate spread of the cancer. The doctor will check for signs of fluid in the neck, armpits, and shoulder areas. Such swelling may be associated with lung cancer pressing on the superior vena cava, a major blood vessel connecting the lungs and heart. Your abdomen will be checked for signs that the liver is affected as well. The doctor will also check the skin for nodules (bumps).
To help your doctor make a diagnosis of lung cancer, some of the following tests may be done:
Chest x-ray – a series of standard x-ray images of your chest to check for abnormal areas on the lungs.
CT scan – a type of x-ray that uses a computer to produce cross-sectional images of the inside of the body, in this case the lungs. A special spiral or helical low dose CT scan may identify smaller tumors than a regular x-ray.
Sputum cytology – examination of a sample of mucus from the lungs to check for cancer cells.
Biopsy – removal of a sample of lung tissue to be tested for cancer cells. Methods of lung biopsy include the following:
Bronchoscopy – a visual examination of the lungs and air passages with a bronchoscope—an instrument with a lighted tip. The doctor can remove tissue samples or wash the tissues with saline (a procedure called lavage) to obtain cells to check for cancer.
Needle aspiration – a needle is inserted through the chest to remove a sample of tissue from the tumor. This tissue is checked for cancer cells.
Thoracentesis – a needle is inserted through the chest to remove a sample of the fluid from around the lungs to check for cancer cells.
Pulmonary function tests – this series of tests is done to see how well your lungs work. The findings from these tests help your doctor determine what kind of treatments may be appropriate for you.
Positron emission tomography (PET) scan - assesses metabolic activity in the tissue. Cancer cells typically generate more activity than non-cancerous cells. A PET scan can be performed on a variety of body tissues. A nurse or technologist administers a radioactive substance. This may be done through an injection, or in some cases, you will be asked to breathe in a gas with the substance. The compound travels through the blood to the area of the body under study. It takes between 30 and 90 minutes for the substance to be absorbed by the tissue under study. You lie on a table and are moved into a machine that looks like a large, square-shaped doughnut. This machine detects and records the energy levels emitted from the substance that was injected earlier. The images are viewed on a nearby computer monitor.
Cytology is the study of cells. The cytology of cancer cells differs significantly from normal cells, and physicians use the unique cellular features seen on biopsy samples to determine the diagnosis and assess the prognosis of a cancer.
To diagnose lung cancer, the cytology of cells from sputum, bronchial washings or brushings, and/or tissue from a biopsy are examined.
Staging is the process by which physicians determine the prognosis of a cancer that has already been diagnosed. Staging is essential for making treatment decisions (e.g., surgery vs. chemotherapy). Several features of the cancer are used to arrive at a staging classification, the most common being the size of the original tumor, extent of local invasion, and spread to distant sites (metastasis). Low staging classifications (0 – 1) imply a favorable prognosis, whereas high staging classifications (4 – 5) imply an unfavorable prognosis.
Additional tests to determine staging may include:
Blood tests - testing of a blood sample may help determine possible cancer spread to other parts of the body.
CT scan – a type of x-ray that uses a computer to produce cross-sectional images of the inside of the body, to look for areas where the cancer may have spread.
MRI scan – a test that uses magnetic waves to produce images of the inside of the body. Using a large magnet, radio waves, and a computer, an MRI produces two-dimensional and three-dimensional pictures. It is used to help determine if the cancer has spread.
Bone or liver scans – tests that look for evidence of tumors in these organs. A radioactive substance is injected into the bloodstream and tracked by a scanning machine. Cancerous areas absorb more of the radioactive substance than normal tissue and show up as “hot spots.”
Lymph node biopsy - your doctor removes all or part of one of your lymph nodes. A pathologist examines this tissue sample under a microscope. The biopsy can show whether or not there is cancer and the type of cancer cells present.
Mediastinoscopy – a test performed in the hospital to check lymph nodes in the chest for cancer cells. The doctor inserts an instrument through a small incision into the chest to remove lymph node tissue, which is then checked for cancer cells.
Lung cancer staging considers three categories: tumor, lymph nodes, and metastases.
Your doctor considers the following factors to determine the stage of lung cancer:
Stage Tis (in situ) - cancer cells are found in the sputum but cannot be seen in the airways or the lung.
Stage T1 - the tumor is 3 centimeters (cm) or smaller, has not spread to the skin or pleura (membrane) that surround the lungs, and is not affecting the main branches of the airways (bronchi).
Stage T2 - the cancer has one or more of the following characteristics:
Stage T3 - the cancer has one or more of the following characteristics:
Stage T4 - the cancer has one or more of the following characteristics:
Stage NO - the cancer has not spread to the lymph nodes.
Stage N1 - the cancer has spread to lymph nodes in the lung or the area where the bronchus meets the lung, and affected the lymph nodes on the same side of the body as the cancer.
Stage N2 - the cancer has spread to the lymph nodes where the windpipe branches left and right, or to lymph nodes in the space between the chest bone and heart. The affected lymph nodes are on the same side of the body as the cancer.
Stage N3 - the cancer has spread to lymph nodes near the collarbone on either side or to the opposite side of the lung from where the lung cancer is located.
Stage MO - the cancer has not spread.
Stage M1 - the cancer has spread to other parts of the body beyond the chest, other lobes of the lung, or lymph nodes beyond those considered in the N stages.
Overall Stage | T Stage | N Stage | M Stage |
---|---|---|---|
Stage 0 | Tis | N0 | M0 |
Stage IA | T1 | N0 | M0 |
Stage IB | T2 | N0 | M0 |
Stage IIA | T1 | N1 | M0 |
Stage IIB | T2 | N1 | M0 |
T3 | N0 | M0 | |
Stage IIIA | T1 | N2 | M0 |
T2 | N2 | M0 | |
T3 | N1 or N2 | M0 | |
Stage IIIB | Any T | N3 | M0 |
T4 | Any N | M0 | |
Stage IV | Any T | Any N | M1 |
Prognosis is a forecast of the probable course and/or outcome of a disease or condition. Prognosis is most often expressed as the percentage of patients who are expected to survive over five or ten years. Cancer prognosis is a notoriously inexact process. This is because the predictions are based on the experience of large groups of patients suffering from cancers at various stages. Using this information to predict the future of an individual patient is always imperfect and often flawed, but it is the only method available. Prognoses provided in this monograph and elsewhere should always be interpreted with this limitation in mind. They may or may not reflect your unique situation.
Stage | 5-year survival rate |
---|---|
Stage I | 85% |
Stage II | 70% |
Stage III | 35% |
Stage IV | 5% |
These rates may vary depending on other prognostic factors. About half of patients with non-small cell lung cancer that is found and treated before it has spread live five or more years. But lung cancer is found at this early stage in only about 17% of patients.
For patients with small cell lung cancer, five-year survival rates are 25% to 30% for early disease and 10% for advanced, metastatic disease.
Sources:
American Cancer Society
American Lung Association
Bast R. Cancer Medicine e5 . Hamilton, Ontario: B.C. Decker Inc.; 2000.
National Cancer Institute
Last reviewed February 2003 by Jondavid Pollock, MD, PhD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.